GeoVax Labs Inc. is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies. Headquartered in Smyrna, Georgia and founded in 1988, the company focuses on addressing unmet medical needs in infectious diseases and oncology. GeoVax Labs Inc. leverages proprietary vaccine platforms to develop preventive vaccines against high-consequence pathogens, including hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, as well as Zika virus, malaria, and human immunodeficiency virus (HIV). In addition, the company is advancing therapeutic candidates targeting solid tumor cancers, using gene-directed and immune-activating approaches to enhance antitumor responses. Its pipeline includes next-generation vaccine candidates and cancer immunotherapies that are evaluated through clinical and preclinical programs. Operating within the broader biotechnology and health technology sectors, GeoVax Labs Inc. plays a specialized role in the market by focusing on complex, often neglected disease areas where robust immune protection or targeted immunotherapy can be particularly important for public health and clinical practice.